Table 2 Rates of patient sustained virological responses and adherence to DAA treatments
Outcomes | DCV+ASV (n = 110) | SOF/LDV (n = 184) | OBV/PTV/r (n = 10) | EBR+GZR (n = 11) | SOF+RBV (n = 85) | OBV/PTV/r +RBV (n = 1) | TOTAL (n = 401) |
|---|---|---|---|---|---|---|---|
Adherence | |||||||
100%, n (%) | 84 (76.4%) | 170 (92.4%) | 10 (100%) | 10 (90.9%) | 65 (76.5%) | 0 (0%) | 339 (84.5%) |
≥95%, n (%) | 109 (99.1%) | 182 (98.9%) | 10 (100%) | 10 (90.9%) | 85 (100%) | 1 (100%) | 397 (99.0%) |
90–94%, n (%) | 0 (0%) | 1 (0.5%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (0.2%) |
<90%, n (%) | 1 (0.9%) | 1 (0.5%) | 0 (0%) | 1 (9.1%) | 0 (0%) | 0 (0%) | 3 (0.7%) |
Completion the treatments, n (%) | 101 | 180 | 9 | 10 | 85 | 1 | 386 |
Achieved SVR12, n (%) a | – | 176/177 (99.4%) | 10/10 (100%) | 2/2 (100%) | 77/77 (100%) | 0/0 (0%) | 265/266 (99.6%) |
Achieved SVR24, n (%) a | 93/99 (93.9%) | – | – | – | – | – | 93/99 (93.9%) |